STOK
Stoke Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$27.68-4.72%
Price as of Jul 20, 2026
STOK financials
Stoke Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $184.4M | $36.6M | $8.8M | $12.4M |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $184.4M | $36.6M | $8.8M | $12.4M |
| Operating expenses | $205.0M | $137.9M | $123.6M | $116.8M |
| Operating income | -$20.6M | -$101.4M | -$114.8M | -$104.4M |
| Net income | -$6.9M | -$89.0M | -$104.7M | -$101.1M |
| EBITDA | -$5.1M | -$86.8M | -$102.2M | -$99.5M |
| Basic EPS | $-0.12 | $-1.65 | $-2.38 | $-2.60 |
| Diluted EPS | $-0.12 | $-1.65 | $-2.38 | $-2.60 |
| Balance sheet | ||||
| Cash & equivalents | $84.2M | $128.0M | $191.4M | $113.6M |
| Total assets | $418.4M | $271.6M | $228.3M | $256.1M |
| Total liabilities | $66.0M | $42.5M | $68.8M | $71.2M |
| Stockholders’ equity | $352.5M | $229.0M | $159.6M | $184.8M |
| Total debt | $3.0M | $4.8M | $2.1M | $2.4M |
| Net debt | -$81.2M | -$123.2M | -$189.4M | -$111.2M |
| Cash flow | ||||
| Operating cash flow | $45.6M | -$86.9M | -$81.1M | -$31.9M |
| Capital expenditure | -$670.0K | -$203.0K | -$1.6M | -$4.0M |
| Free cash flow | $44.9M | -$87.1M | -$82.7M | -$35.8M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |